Romidepsin News and Research

RSS
Cyclacel files Answer and Counterclaims to Celgene's declaratory judgment complaint

Cyclacel files Answer and Counterclaims to Celgene's declaratory judgment complaint

Celgene seeks court declaration over claims of romidepsin injection usage for T-cell lymphomas

Celgene seeks court declaration over claims of romidepsin injection usage for T-cell lymphomas

Celgene reports total revenue of $758M for fourth-quarter of 2009

Celgene reports total revenue of $758M for fourth-quarter of 2009

Celgene acquires Gloucester Pharmaceuticals

Celgene acquires Gloucester Pharmaceuticals

Gloucester Pharmaceuticals to be acquired by Celgene

Gloucester Pharmaceuticals to be acquired by Celgene

Positive data from Gloucester Pharmaceuticals' ISTODAX study presented at the ASH meeting

Positive data from Gloucester Pharmaceuticals' ISTODAX study presented at the ASH meeting

Presentation of preclinical data demonstrating the combination of ISTODAX and Velcade announced

Presentation of preclinical data demonstrating the combination of ISTODAX and Velcade announced

Positive final data from Phase 2 study of ISTODAX presented

Positive final data from Phase 2 study of ISTODAX presented

ISTODAX included in the updated NCCN Clinical Practice Guidelines in Oncology

ISTODAX included in the updated NCCN Clinical Practice Guidelines in Oncology

Multiple presentations from clinical and preclinical studies of ISTODAX to be presented

Multiple presentations from clinical and preclinical studies of ISTODAX to be presented

NCCN Guidelines adds ofatumumab and romidepsin as therapy options for CLL

NCCN Guidelines adds ofatumumab and romidepsin as therapy options for CLL

FDA approves Istodax for treatment of Cutaneous T-cell Lymphoma

FDA approves Istodax for treatment of Cutaneous T-cell Lymphoma

Gloucester’s romidepsin recommended for approval by the FDA Oncologic Drug Advisory Committee

Gloucester’s romidepsin recommended for approval by the FDA Oncologic Drug Advisory Committee

Gloucester Pharmaceuticals raises funds for the development of romidepsin

Gloucester Pharmaceuticals raises funds for the development of romidepsin

Gloucester Pharma announces FDA Advisory Committee Meeting to discuss Romidepsin NDA

Gloucester Pharma announces FDA Advisory Committee Meeting to discuss Romidepsin NDA

Researchers induce cell death in leukemia

Researchers induce cell death in leukemia

CuraGen announces results with Belinostat and Velafermin

CuraGen announces results with Belinostat and Velafermin